Results 161 to 170 of about 3,128,159 (361)

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen   +3 more
wiley   +1 more source

Body surface temperatures as biomarkers of physiological environmental adaptation in wild birds and mammals

open access: yesBiological Reviews, EarlyView.
ABSTRACT The ability of individuals to cope with their environment, and therefore the likelihood that they survive and pass on their genes (i.e. fitness), is largely determined by physiological state. Tracking physiological state in wild animals, however, is challenging.
Paul Jerem, L. Michael Romero
wiley   +1 more source

GWAS Identifies SNPs Associated With Severe Adverse Events and Efficacy in Advanced Renal Cell Carcinoma Treated With Nivolumab

open access: yesCancer Science, EarlyView.
This study highlights the importance of germline genetic markers in predicting severe trAEs caused by nivolumab. Our findings support their potential to guide personalized immunotherapy and improve treatment safety and efficacy in advanced ccRCC and other cancers.
Tokiyoshi Tanegashima   +26 more
wiley   +1 more source

Targeting Autophagy for Pituitary Tumors. [PDF]

open access: yesCancers (Basel)
Yin E, Satou M, Tateno T.
europepmc   +1 more source

Reprimo (RPRM): A Tumor Suppressor That Induces Extrinsic Apoptosis via YAP Signaling

open access: yesCancer Science, EarlyView.
Reprimo (encoded by RPRM) is a p53 target gene that acts as a tumor suppressor and is frequently silenced by promoter hypermethylation in various cancers. Although previously known to function intracellularly as a tumor suppressor, recent studies revealed that secreted Reprimo also induces apoptosis in neighboring cells through a novel p53‐Reprimo ...
Masahiro Takikawa, Rieko Ohki
wiley   +1 more source

Development of a Minimum Dataset for the Global Monitoring of the Safety and Efficacy of Growth Hormone Replacement in Adults With Growth Hormone Deficiency (AGHD)

open access: yesClinical Endocrinology, EarlyView.
ABSTRACT Objective To identify the minimum dataset (MDS) for the monitoring of safety and effectiveness of GH in adults with growth hormone deficiency (AGHD). Design Systematic review and expert consensus. Methods Outcomes for AGHD were identified through a systematic literature search in PubMed, Science Direct and Cochrane.
Suet Ching Chen   +26 more
wiley   +1 more source

Home - About - Disclaimer - Privacy